The stock of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) is a huge mover today! About 52,764 shares traded hands. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has declined 39.13% since April 5, 2016 and is downtrending. It has underperformed by 41.09% the S&P500.
The move comes after 5 months positive chart setup for the $35.68 million company. It was reported on Nov, 7 by Barchart.com. We have $4.76 PT which if reached, will make NASDAQ:GLMD worth $14.99M more.
Analysts await Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) to report earnings on November, 14. They expect $-0.38 earnings per share, down 65.22% or $0.15 from last year’s $-0.23 per share. After $-0.39 actual earnings per share reported by Galmed Pharmaceuticals Ltd for the previous quarter, Wall Street now forecasts -2.56% EPS growth.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Ratings Coverage
Out of 2 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Galmed Pharmaceuticals Ltd has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. Roth Capital maintained the shares of GLMD in a report on Thursday, August 13 with “Buy” rating. H.C. Wainwright reinitiated Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) rating on Monday, March 28. H.C. Wainwright has “Buy” rating and $22 price target.
According to Zacks Investment Research, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.”
More notable recent Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) news were published by: Marketwatch.com which released: “Galmed Pharmaceuticals stock price target cut to $9 from $24 at Maxim Group” on March 13, 2014, also Prnewswire.com with their article: “Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the …” published on July 28, 2016, Prnewswire.com published: “Galmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D …” on September 08, 2016. More interesting news about Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) were released by: Prnewswire.com and their article: “Galmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” published on August 03, 2016 as well as Prnewswire.com‘s news article titled: “Galmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D …” with publication date: August 01, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.